Market research
FRE.F Fresenius SE & Co. KGaA
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 26B
- P/E ratio
- 16.58
- Analyst target
- 55.5857
- Dividend yield
- 2.3%
- Beta
- 0.83
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- ISIN
- DE000FRE5EN2
- Market cap
- 26B
- P/E ratio
- 16.58
- Analyst target
- 55.5857
- Dividend yield
- 2.3%
- Beta
- 0.83
About
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FRE.F discussion.
5 years, 5 months ago
Fresenius SE & Co. KGaA is currently in a long term uptrend where the price is trading 12.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Fresenius SE & Co. KGaA's total revenue sank by 0.1% to $9B since the same quarter in the previous year.
Its net income has dropped by 20.4% to $410M since the same quarter in the previous year.
Finally, its free cash flow grew by 28.9% to $562M since the same quarter in the previous year.
Based on the above factors, Fresenius SE & Co. KGaA gets an overall score of 3/5.